




Instance: composition-en-82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: CompositionUvEpi
Title: "Composition for replagal Package Leaflet"
Description:  "Composition for replagal Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp451b278e032c6d6b351288ef6c2fe7fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - replagal"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Replagal is and what it is used for</li>
<li>What you need to know before you are given Replagal</li>
<li>How Replagal is given</li>
<li>Possible side effects</li>
<li>How to store Replagal</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What replagal is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What replagal is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The active substance in Replagal is agalsidase alfa (1 mg/ml). Agalsidase alfa is a form of the human 
enzyme  -galactosidase. It is produced by switching on the gene for  -galactosidase A in cells. The 
enzyme is then removed from the cells and made into a sterile concentrate for solution for infusion.
Replagal is used to treat adult patients, as well as adolescents and children from the age of 7, with 
confirmed diagnosis of Fabry Disease. It is used as long-term enzyme replacement therapy when the 
level of enzyme in the body is absent or lower than normal as in Fabry Disease.
After 6 months of therapy Replagal significantly reduced pain in patients when compared to placebo 
(dummy) treated patients. Replagal reduced left ventricle mass in treated patients compared to placebo
treated patients. These results suggest the symptoms of the disease are improving or the disease is 
becoming stable.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>You must not be given Replagal</h2>
<p>if you are allergic to agalsidase alfa or any of the other ingredients of this medicine (listed in 
section 6).
Warnings and precautions
Talk to your doctor or pharmacist before Replagal is used.
If you notice any of these effects during or after an infusion you should tell your doctor immediately:
-
high fever, chills, sweating, fast heart rate.
-
vomiting.
-
light-headedness.
-
hives.
-
swelling in your hands, feet, ankles, face, lips, mouth or throat which may cause difficulty in 
swallowing or breathing.
Your doctor may stop the infusion temporarily (5   10 min) until the symptoms go away and then 
begin the infusion again.
Your doctor may also treat the symptoms with other medicines (antihistamines or corticosteroids).
Most of the time you can still be given Replagal even if these symptoms occur.
If you experience a severe allergic (anaphylactic-type) reaction, the administration of Replagal will be 
immediately discontinued and an appropriate treatment will have to be initiated by your doctor.
If treatment with Replagal makes your body produce antibodies this will not stop Replagal from 
working and the antibodies may disappear with time.
If you have advanced renal disease, you may find that your Replagal treatment has a limited effect on 
your kidneys. Talk to your doctor or pharmacist before using Replagal.
Children
The experience in children 0-6 years old is limited and therefore no dose can be recommended for this 
age group.
Other medicines and Replagal
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.
Tell your doctor if you use any medicines containing chloroquine, amiodarone, benoquin or
gentamicin. There is a theoretical risk of decreased agalsidase alfa activity.
Pregnancy and breast feeding
Very limited clinical data on pregnancies exposed to Replagal have shown no adverse effects on the 
mother and newborn child. 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may drive and use machines whilst on Replagal.
Replagal contains sodium
This medicine contains 14.2 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 0.7% of the recommended maximum daily dietary intake of sodium for an adult.
Keeping a record
In order to improve the traceability of biological medicinal products, the name and batch number of 
the administered product should be clearly recorded by your healthcare professional. Speak with your 
healthcare professional if you are not sure.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This medicine should be applied and supervised by appropriately trained personnel, who will also 
calculate the dose that you will be given. While remaining under the physician s supervision, Replagal 
can be self-administered (by you or your caregiver) after appropriate training by the treating physician
and/or nurse. Self-administration should occur in the presence of a responsible adult.
The recommended dose is an infusion of 0.2 mg for every kg you weigh. This would be about 14 mg 
or 4 vials (glass bottles) of Replagal for an average size (70 kg) individual.
Use in children and adolescents
For children and adolescents 7-18 years old a dose of 0.2 mg/kg every other week may be used.
Children and adolescents may be more likely than adults to experience an infusion related reaction.
Tell your doctor if you experience any side effects whilst having the infusion.
Method of administration
Replagal has to be diluted in 9 mg/ml (0.9%) sodium chloride solution before use. After dilution 
Replagal is given in a vein. This will usually be in your arm.
The infusion will be given every two weeks.
Each time you are treated it will take 40 minutes for Replagal to be given to you in a vein. Your 
treatment will be supervised by a doctor who specialises in the treatment of Fabry Disease.
For self-administration, the dose and rate of infusion given should not be changed without the 
agreement of the treating physician.
If you use more Replagal than you should
If you believe you have used more Replagal than you should, please contact your doctor.
If you use less Replagal than you should
If you believe you have used less Replagal than you should, please contact your doctor.
If you forget to use Replagal
If you have missed an infusion of Replagal, please contact your doctor.
If you stop using Replagal
Do not stop using Replagal without contacting your doctor. If you have any further questions on the 
use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience a severe allergic (anaphylactic-type) reaction, the administration of Replagal will be 
immediately discontinued and an appropriate treatment will have to be initiated by your doctor.
Most side effects are mild to moderate. More than 1 in 10 people (frequency  very common ) may 
have a reaction during or following an infusion of Replagal (infusion related reaction). These effects 
include chills, headache, nausea, fever, tiredness, unsteadiness, difficulty breathing, shaking, cough 
and vomiting. However, some effects may be serious and may need treatment. Infusion related 
reactions involving the heart including heart muscle ischemia and heart failure, may occur in patients 
with Fabry disease involving the heart structures (frequency  not known  (cannot be estimated from 
the available data)). Your doctor may stop the infusion temporarily (5 - 10 min) until the symptoms go 
away and then begin the infusion again. Your doctor may also treat the symptoms with other
medicines (antihistamines or corticosteroids). Most of the time you can still be given Replagal even if 
these symptoms occur.
List of other side effects:
Very common: may affect more than 1 in 10 people
-
swelling in the tissue (e.g., legs, arm)
-
tingling or numbness or pain in fingers or toes
-
ear ringing
-
palpitations
-
Sore throat
-
abdominal pain, diarrhoea
-
rash 
-
back or limb pain, muscle pain, joint pain
-
chest pain, cold symptoms, fever, feeling sick
Common: may affect up to 1 in 10 people:
-
change in the taste of food, prolonged sleep
-
eyes tearing
-
increased ear ringing
-
increased heart rate, heart rhythm problems
-
increased blood pressure, low blood pressure, facial flushing (redness)
-
hoarseness, or tight throat, runny nose
-
abdominal discomfort
-
acne, red or itchy or mottled skin, excessive sweating
-
muscle and bone discomfort, swelling of the extremities or joints
-
hypersensitivity
-
chest tightness, increased feeling lack of energy, feeling cold or hot, flu-like symptoms,
discomfort
Uncommon: may affect up to 1 in 100 people:
-
severe allergic (anaphylactic-type) reaction
-
blink reflex abnormal
-
increased heart rate
-
low level of oxygen in your blood and sticky throat secretions
-
sense of smell is different)
-
collection of fluid under the skin may lead to swelling of body parts, lace-like discoloration of the 
skin e.g., in the leg
-
sensation of heaviness
-
injection site rash
Children and adolescents
Side effects reported in children were, in general, similar to those reported in adults. However, 
infusion related reactions (fever, difficulty breathing, chest pain) and pain aggravated occurred more 
frequently.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 
expiry date refers to the last day of that month.
Store in a refrigerator (2  C   8  C). 
Do not use Replagal if you notice that there is discolouration or other foreign particles present.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Replagal contains</h2>
<h2>The active substance is agalsidase alfa. Each ml of Replagal contains 1 mg of agalsidase alfa.</h2>
<p>The other ingredients are: Sodium phosphate monobasic, monohydrate
Polysorbate Sodium chloride
Sodium hydroxide
Water for injections
Replagal contains sodium. See section 2. What Replagal looks like and contents of the pack
Replagal is a concentrate for solution for infusion. Your medicine is available in vials containing 
3.5 mg/ 3.5 ml of agalsidase alfa. Pack sizes of 1, 4 or 10 vials are available. Not all pack sizes may be 
marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50 58 Baggot Street Lower 
Dublin 2
D02 HWIreland
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50 58 Baggot Street Lower 
Dublin 
D02 HWIreland
Shire Pharmaceuticals Ireland Limited
Block 2 &amp; 3 Miesian Plaza
50 58 Baggot Street Lower
Dublin 2
Ireland
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com
Luxembourg/Luxemburg
Takeda Belgium NV
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
 akeda HELLAS S.A.
Tel: +30 210 6387medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>akeda    . .
T : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
Espa a
Takeda Farmac utica Espa a S.A
Tel: +34 917 90 42 medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel: +48223062medinfoEMEA@takeda.com
France
Takeda France SAS
T l. + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Takeda Farmac uticos Portugal, Lda.
Tel: + 351 21 120 1medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>akeda    . .
 : +30 210 6387medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in . 
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: CompositionUvEpi
Title: "Composition for replagal Package Leaflet"
Description:  "Composition for replagal Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp451b278e032c6d6b351288ef6c2fe7fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - replagal"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse <br />
2. Det skal De vide, før De får Replagal
3. Sådan får De Replagal
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What replagal is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What replagal is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Det aktive stof er agalsidase alfa (1 mg/ml). Agalsidase alfa er en form af det humane enzym 
α-galactosidase. Det fremstilles ved at tænde for genet for α-galaktosidase A i celler. Enzymet fjernes 
dernæst fra cellen og omdannes til et sterilt koncentrat til opløsning til infusion.
Replagal anvendes til behandling af voksne patienter samt børn og unge i alderen 7 år og opefter med 
en bekræftet diagnose på Fabrys sygdom. Det anvendes som langtidsvarende enzym-
substitueringsterapi, når mængden af enzym i kroppen er lavere end normalt, således som det ses ved 
Fabrys sygdom.
Efter 6 måneders behandling reducerede Replagal signifikant patienternes smerter sammenlignet med 
smerterne hos patienter, der blev behandlet med placebo (uvirksomt stof). Replagal reducerede 
patienternes venstre hjertekammer sammenlignet med hjertekammeret hos placebobehandlede 
patienter. Disse resultater tyder på, at sygdommens symptomer mindskes, eller at sygdommen 
stabiliseres.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>De må ikke få Replagal</h2>
<p>hvis De er allergisk over for agalsidase alfa eller et af de øvrige indholdsstoffer angivet i 
punkt 6. Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De får Replagal.
Hvis De bemærker nogen af nedenstående bivirkninger under eller efter en infusion, skal De straks 
give Deres læge besked:
-
høj feber, kulderystelser, øget svedtendens, hurtig hjerterytme (puls)
24
-
opkastning
-
svimmelhed
-
nældefeber
-
hævelse af hænder, fødder, ankler, ansigt, læber, mund eller hals, hvilket kan give problemer 
med at synke eller trække vejret.
Deres læge kan afbryde infusionen midlertidigt (5-10 min), indtil symptomerne forsvinder, og dernæst 
genoptage infusionen.
Deres læge kan også behandle symptomerne med andre lægemidler (antihistaminer eller 
kortikosteroider). Som regel kan De stadig få Replagal, selvom disse symptomer indtræder. 
Hvis der indtræder alvorlige allergiske (anafylaktiske) reaktioner, vil indgivelsen af Replagal straks 
blive standset, og lægen vil skulle iværksætte en passende behandling.
Hvis behandlingen med Replagal får Deres krop til at danne antistoffer, vil det ikke forhindre, at 
Replagal virker, og antistofferne kan forsvinde med tiden.
Hvis De har fremskreden nyresygdom, kan det være, at Replagal-behandlingen har en begrænset 
virkning på Deres nyrer. Tal med lægen eller apotekspersonalet, før De tager Replagal.
Børn
Der er kun begrænset erfaring med børn i alderen 0-6 år, og derfor kan der ikke anbefales nogen dosis 
for denne aldersgruppe.
Brug af anden medicin sammen med Replagal
Fortæl det altid til lægen eller apotekspersonalet, hvis De tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. 
Fortæl det til lægen, hvis De tager medicin, der indeholder chloroquin, amiodaron, benoquin eller
gentamicin. Der er en teoretisk risiko for nedsat agalsidase alfa-aktivitet.
Graviditet og amning
Meget begrænsede kliniske data om graviditeter, der er blevet eksponeret for Replagal, har ikke vist 
nogen bivirkninger på moderen og det nyfødte barn. 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De får dette lægemiddel.
Trafik- og arbejdssikkerhed
De kan føre motorkøretøj og betjene maskiner, medens De anvender Replagal.
Replagal indeholder natrium
Dette lægemiddel indeholder 14,2 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
hætteglas. Dette svarer til 0,7 % af den anbefalede maksimale daglige indtagelse af natrium for en 
voksen.
Registrering
For at forbedre sporbarheden af biologiske lægemidler skal det indgivne produkts navn og 
batchnummer tydeligt registreres af Deres læge eller sygeplejerske. Tal med Deres læge eller 
sygeplejerske, hvis De er i tvivl.
25</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel skal indgives af særligt uddannet personale, der også udregner den dosis, som De 
skal have. Replagal kan selvadministreres under stadigt tilsyn af lægen (af dig selv eller din 
omsorgsgiver) efter passende træning af den behandlende læge og/eller sygeplejerske. 
Selvadministration skal ske under tilstedeværelse af en ansvarlig voksen.
Den anbefalede dosis er en infusion af 0,2 mg/kg legemsvægt. Dette vil være ca. 14 mg eller 
4 hætteglas (glasflasker) Replagal for et individ af normalstørrelse (70 kg). 
Brug til børn og unge
For børn og unge i alderen 7-18 år anbefales en dosis på 0,2 mg/kg hver anden uge.
Børn og unge kan være mere tilbøjelige end voksne til at få en infusionsrelateret reaktion. Fortæl det 
til lægen, hvis De får bivirkninger under infusionen.
Indgivelsesmåde
Replagal skal fortyndes med 9 mg/ml (0,9%) natriumchlorid-infusionsvæske før anvendelse. Efter 
fortynding indgives Replagal i en vene. Det vil sædvanligvis være i armen.
Infusionen vil blive givet hver anden uge.
Hver gang De bliver behandlet, vil det tage 40 minutter at indgive Replagal i en vene. De vil blive 
behandlet under vejledning af en læge, som er specialiseret i behandling af Fabrys sygdom.
Dosis- og infusionshastigheden ved selvadministration, må ikke ændres uden den behandlende læges 
accept.
Hvis De har taget for meget Replagal
Kontakt lægen, hvis De tror, at De har taget for meget Replagal.
Hvis De har taget for lidt Replagal
Kontakt lægen, hvis De tror, at De har taget for lidt Replagal.
Hvis De har glemt at tage Replagal
Kontakt lægen, hvis De har glemt en infusion af Replagal.
Hvis De holder op med at tage Replagal
De må ikke holde op med at tage Replagal uden at tale med lægen. Spørg lægen eller 
apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Hvis De får en alvorlig allergisk (anafylaktisk) reaktion, vil Replagal-infusionen straks blive standset, 
og reaktionen skal behandles af lægen med det samme.
26
De fleste bivirkninger er lette til moderate. Flere end 1 ud af 10 behandlede personer (meget 
almindelig bivirkning) kan have en reaktion under eller efter en infusion med Replagal 
(infusionsrelateret reaktion). Disse bivirkninger inkluderer kuldegysninger, hovedpine, kvalme, feber, 
træthed, usikkerhed, åndedrætsbesvær, rysten, hoste og opkastning. Imidlertid kan nogle bivirkninger 
være alvorlige og nødvendiggøre behandling. Infusionsrelaterede reaktioner, der berører hjertet, 
herunder manglende blodtilførsel til hjertemusklen og hjertesvigt, kan opstå hos patienter med Fabrys 
sygdom, hvor hjertet er påvirket (hyppigheden er ikke kendt (kan ikke vurderes ud fra tilgængelige 
data). Lægen kan standse infusionen midlertidigt (5-10 min), indtil symptomerne er forsvundet, og så 
genoptage infusionen igen. Lægen kan også behandle symptomerne med andre lægemidler 
(antihistaminer eller kortikosteroider). De kan som oftest stadig kunne få Replagal, selvom De får 
disse symptomer.
Andre bivirkninger:
Meget almindelige: kan forekomme hos flere end 1 ud af 10 personer:
-
opsvulmet væv (f.eks. ben, arm)
-
prikken eller følelsesløshed eller smerter i fingre eller tæer
-
ringen for ørerne
-
hjertebanken
-
ondt i halsen
-
mavesmerter, diarre
-
udslæt
-
rygsmerter eller smerter i arme/ben, muskelsmerter, ledsmerter
-
brystsmerter, forkølelsessymptomer, feber, kvalme
Almindelige: kan forekomme hos op til 1 ud af 10 personer:
-
ændret smagssans, forlænget søvn 
-
tåreflåd
-
øget ringen for ørerne
-
øget hjertefrekvens (puls), problemer med hjerterytmen 
-
forhøjet blodtryk, for lavt blodtryk, ansigtsrødme
-
hæshed eller følelse af tranghed i halsen, næseflåd
-
maveubehag
-
acne, rød eller kløende eller marmoreret hud, kraftig sveden
-
muskel- og knogleubehag, hævede lemmer eller led
-
overfølsomhed
-
trykken for brystet, øget følelse af manglende energi, kuldefornemmelse eller varmefornemmelse, 
influenzalignende symptomer, ubehag
Ikke almindelige: kan forekomme hos op til 1 ud af 100 personer:
-
alvorlig allergisk (anafylaktisk) reaktion
-
unormal blinkerefleks
-
øget hjertefrekvens (puls)
-
lavt iltniveau i blodet og klægt udflåd fra halsen
-
ændret lugtesans
-
væskeansamling under huden, der kan medføre hævede kropsdele; blondelignende misfarvning af
huden, f.eks. på benet
-
tyngdefornemmelse
-
udslæt på injektionsstedet
Hos børn og unge kan endvidere ses følgende bivirkninger:
De bivirkninger, der blev indberettet i forbindelse med brug hos børn, var generelt de samme som 
dem, der blev indberettet ved brug hos voksne. Infusionsrelaterede reaktioner (feber, 
åndedrætsbesvær, brystsmerter) og forværrede smerter sås dog med større hyppighed.
27
Indberetning af bivirkninger
Hvis De oplever bivirkninger, bør De tale med Deres læge, apotekspersonalet eller sygeplejersken. 
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store replagal"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store replagal"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned.
Opbevares i køleskab (2 °C - 8 °C).
Brug ikke Replagal, hvis De bemærker misfarvning eller tilstedeværelse af andre fremmede partikler.
Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Replagal indeholder:</h2>
<h2>Aktivt stof: agalsidase alfa. Hver ml Replagal indeholder 1 mg agalsidase alfa.</h2>
<p>Øvrige indholdsstoffer:    natriumdihydrogenphosphatmonohydrat
polysorbat natriumchlorid 
natriumhydroxid 
vand til injektionsvæsker 
Replagal indeholder natrium. Se punkt 2. Udseende og pakningsstørrelser
Replagal er et koncentrat til infusionsvæske, opløsning. Lægemidlet leveres i hætteglas (glasflasker) 
indeholdende 3,5 mg/3,5 ml agalsidase alfa. Pakker kan indeholde 1,4 eller 10 hætteglas per karton. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Indehaver af markedsføringstilladelsen
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2
D02 HW68
Irland
28
Fremstiller
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HW68
Irland
Shire Pharmaceuticals Ireland Limited
Block 2 &amp; 3 Miesian Plaza
50 - 58 Baggot Street Lower
Dublin 2
Irland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Takeda Belgium NV
Tel/Tél: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com
България
Такеда България ЕООД
Тел.: +359 2 958 27 36
medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
Tel/Tél: +32 2 464 06 11
medinfoEMEA@takeda.com
Česká republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com
Magyarország
Takeda Pharma Kft.
Tel: +36 1 270 7030
medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 10
medinfoEMEA@takeda.com
Malta
Τakeda HELLAS S.A.
Tel: +30 210 6387800
medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 669
medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com
Ελλάδα
Τakeda ΕΛΛΑΣ Α.Ε.
Tηλ: +30 210 6387800
medinfoEMEA@takeda.com
Österreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
España
Takeda Farmacéutica España S.A
Tel: +34 917 90 42 22
medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel: +48223062447
medinfoEMEA@takeda.com
29
France
Takeda France SAS
Tél. + 33 1 40 67 33 00
medinfoEMEA@takeda.com
Portugal
Takeda Farmacêuticos Portugal, Lda.
Tel: + 351 21 120 1457
medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com
România
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska družba d.o.o.
Tel: + 386 (0) 59 082 480
medinfoEMEA@takeda.com
Ísland
Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com
Slovenská republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com
Κύπρος
Τakeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840082
medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 902
medinfoEMEA@takeda.com
Denne indlægsseddel blev senest ændret .
Andre informationskilder
De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles.</p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale:
Instruktioner vedrørende anvendelse og håndtering samt bortskaffelse
Behandling med Replagal skal ske under supervision af en læge med erfaring i behandling af patienter 
med Fabrys sygdom eller andre arvelige metaboliske sygdomme.
Replagal indgives i en dosis på 0,2 mg/kg legemsvægt hver anden uge som en intravenøs infusion over 
40 minutter.
1. Beregn den nødvendige dosis og antallet af hætteglas med Replagal.
30
2. Fortynd det totale volumen Replagal koncentrat, som er nødvendig i 100 ml 9 mg/ml 
natriumchloridinfusionsvæske (0,9% vægt/vol). Der skal udvises omhu med hensyn til at sikre 
steriliteten af den fremstillede opløsning, da Replagal ikke indeholder noget 
konserveringsmiddel eller bakteriestatisk middel. Der må iagttages aseptisk teknik. Efter 
fortynding bør opløsningen blandes blidt, men uden omrystning.
3. Opløsningen bør inspiceres visuelt for indhold af partikulært materiale og misfarvning forud for 
indgift.
4. Indgiv infusionsvæsken over en periode af 40 minutter ved anvendelse af en intravenøs slange 
med et integreret filter. Da der ikke er noget konserveringsmiddel i, anbefales det, at indgift 
påbegyndes så hurtigt som muligt. Kemisk og fysisk stabilitet af den fortyndede opløsning er 
imidlertid demonstreret i 24 timer ved 25 oC.
5. Replagal må ikke infunderes samtidigt i samme intravenøse slange som andre lægemidler.
6. Kun til engangsbrug. Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til
lokale retningslinjer.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for replagal Package Leaflet for language en"
Description: "ePI document Bundle for replagal Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-82ed3b7e13571c65c8c961f4a21dd3e2"
* entry[0].resource = composition-en-82ed3b7e13571c65c8c961f4a21dd3e2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp82ed3b7e13571c65c8c961f4a21dd3e2"
* entry[=].resource = mp82ed3b7e13571c65c8c961f4a21dd3e2
                            
                    
Instance: bundlepackageleaflet-da-82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for replagal Package Leaflet for language da"
Description: "ePI document Bundle for replagal Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-82ed3b7e13571c65c8c961f4a21dd3e2"
* entry[0].resource = composition-da-82ed3b7e13571c65c8c961f4a21dd3e2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp82ed3b7e13571c65c8c961f4a21dd3e2"
* entry[=].resource = mp82ed3b7e13571c65c8c961f4a21dd3e2
                            
                    



Instance: mp82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product replagal"
Description: "replagal"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/01/189/001-003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "replagal"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 82ed3b7e13571c65c8c961f4a21dd3e2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "replagal"

* status = #current
* mode = #working

* title = "List of all ePIs associated with replagal"

* subject = Reference(mp451b278e032c6d6b351288ef6c2fe7fa)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#replagal "replagal"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-82ed3b7e13571c65c8c961f4a21dd3e2) // replagal en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-82ed3b7e13571c65c8c961f4a21dd3e2) // replagal da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-82ed3b7e13571c65c8c961f4a21dd3e2
InstanceOf: List

* insert 82ed3b7e13571c65c8c961f4a21dd3e2ListRuleset
    